Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook

Thelansis’s “Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chimeric Antigen Receptor (CAR) T-Cell Therapy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chimeric Antigen Receptor (CAR) T-Cell Therapy Overview

Chimeric Antigen Receptor (CAR) T-cell therapy is an advanced immunotherapy used to treat certain types of cancer. It involves genetically modifying a patient’s T-cells to express a chimeric antigen receptor on their surface, allowing them to recognize and attack cancer cells expressing specific antigens.

The CAR T-cell therapy process includes the following:

1. Collection of T-cells from the patient’s blood through leukapheresis
2. Genetic engineering of T-cells in the lab using a viral vector to introduce the CAR gene
3. Expansion of genetically modified T-cells to produce a large number of CAR T-cells
4. Infusion of the CAR T-cells back into the patient’s bloodstream
5. Targeting and destruction of cancer cells by activated CAR T-cells

The market for CAR T-cell therapy has been rapidly growing due to its high success rates in treating blood cancers and its potential in other malignancies. Pharmaceutical and biotech companies have invested significantly in developing CAR T-cell therapies and conducting clinical trials to expand their scope. EMA and FDA have approved CAR T-cell therapies for different indications. Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) were the first CAR T-cell therapies to receive approval for certain forms of leukemia and lymphoma.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034